-
Mashup Score: 25Trailblazers, iconoclasts and breakthrough artists are coming to the Endpoints biotech summit — please join us - 3 day(s) ago
When Aviv Regev closed out one long chapter of her life at the Broad and stepped into a new job as head of research and early development at Genentech four years ago, she set out to build a whole new approach to drug discovery on top of the broad base
Source: endpts.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 23
Apellis received $375 million in funding at close, with ability to access an additional $100 million Majority of initial proceeds used to buy out existing SFJ Pharmaceuticals development liability Significantly improves liquidity profile by eliminating $366 million in SFJ payments through 2027 WALTHAM, Mass., May 14, 2024 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today annou nced that it has entered into a non-dilutive, senior secured credit facility with Sixth Street, a leading
Source: investors.apellis.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 22
More details have started to emerge on how exactly Bayer is executing its broader company restructuring. The German conglomerate disclosed that 1,500 full-time employees had been laid off across pharmaceuticals, crop science and consumer health at the end of the first quarter. The company previously described plans for staff cuts
Source: endpts.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 12Sanofi takes on Novavax's Covid vaccine for $500M, eyeing commercialization, flu combination - 7 day(s) ago
Sanofi is handing Novavax $500 million upfront to bring the biotech’s Covid-19 vaccine into the fold, with dual goals of co-commercializing the current vaccine and developing combo vaccines that can tackle both Covid and flu. The deal also carries $700 million in development, regulatory and launch milestones, meaning Novavax can
Source: endpts.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 29Takeda to shut down San Diego research center - 8 day(s) ago
Takeda is shuttering its San Diego research site, the company confirmed to Endpoints News. The company told employees on Thursday that it will close the site as part of a decision “to focus more of our resources on our promising late-stage pipeline and to ensure we are best positioned to
Source: endpts.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 2After CRISPR baby scandal shut down work for years, China gene editing companies are restarting clinical trials - 9 day(s) ago
A half-decade after a scientist’s reckless experiment with human embryos put a stop to much of China’s clinical work on CRISPR gene editing, local researchers are once again performing human studies of the technology. At least three Chinese biotech companies have recently begun tests of CRISPR treatments for blood, eye
Source: endpts.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 5AstraZeneca pulls Covid-19 vaccine globally as the pharma sees 'no future commercial demand' - 9 day(s) ago
AstraZeneca is withdrawing its Oxford-collaborated Covid-19 vaccine from global markets, the UK-based pharma company confirmed in a statement to Endpoints News on Tuesday. The spokesperson said AstraZeneca no longer manufactures or supplies the vaccine, which was first cleared for emergency supply in the UK in December 2020 and had since
Source: endpts.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0World’s Biggest Construction Project Gets a Reality Check - 10 day(s) ago
Saudi Arabia’s plans for twin 100-mile-long skyscrapers have lost momentum amid spiraling costs and construction glitches.
Source: www.wsj.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 2Exclusive: Feng Zhang CRISPR startup gathers patents, locking up rights to family of editing tech - 10 day(s) ago
In the bid to lock up patent rights to a growing suite of gene-editing technologies, Arbor Biotechnologies has acquired a small startup founded by MIT scientist and CRISPR pioneer Feng Zhang, the company exclusively told Endpoints News. Zhang’s startup, Serendipity Bioscience, has never disclosed how much funding it raised, and
Source: endpts.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 4
In the midst of the Covid-19 pandemic, while most scientists were busy plotting new ways to combat viruses, one startup quietly began a counterintuitive campaign: getting viruses to work for us, instead of against us. Now, after three years in stealth, Prologue Medicines launched Tuesday morning and unveiled its plan
Source: endpts.comCategories: General Medicine News, General HCPsTweet
Hey, if you're planning to be in San Diego June 3, we've got a biotech event planned you should check out. I'll be chatting with Aviv Regev, Matt Gline and others. https://t.co/r1w0aEUpNE